Physician profile
Amanda Meier
NPI 1306415807
$879.63
in general payments reported to CMS, 2019-2025
12 companies · $536 in 2025
The $536 reported for 2025 was more than what 75% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $39.57 · 2023: $20.43 · 2024: $283 · 2025: $536.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $840.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $840.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $277.12 | 2024-2025 | Breztri, Airsupra, Farxiga |
| Glaxosmithkline, LLC. | $150.67 | 2025 | Arexvy, Shingrix |
| Sanofi-Aventis U.S. LLC | $95.91 | 2024-2025 | |
| Lilly USA, LLC | $83.96 | 2024-2025 | Mounjaro, Zepbound, Kisunla |
| Abbvie INC. | $72.12 | 2023-2025 | |
| Novo Nordisk INC | $65.10 | 2024-2025 | Wegovy, Rybelsus, Ozempic |
| Almatica Pharma LLC | $43.34 | 2024-2025 | Loreev Xr |
| Bayer Healthcare Pharmaceuticals INC. | $22.37 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $20.55 | 2024 | Trulance, Xifaxan |
| Otsuka America Pharmaceutical, INC. | $17.72 | 2025 | Rexulti |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $17.20 | 2021 | |
| Exact Sciences Corporation | $13.57 | 2025 | Cologuard Collection Kit |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amanda Meier listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.